anti-C100-3

02/01/1994 - "Despite the use of the anti-c100-3 assay for blood donor screening, posttransfusion non-A,non-B hepatitis still occurred. "
07/12/1993 - "None of the remaining 87 recipients had any clinical or laboratory evidence of hepatitis during follow-up, or experienced seroconversion for anti-C100-3 or second-generation anti-HCV. "
05/01/1993 - "Anti-HCVcore was detected with high titers in 95% (69/73) of chronic non-A, non-B hepatitis patients, while anti-C100-3 was found in 60% (44/73). "
04/08/1992 - "These results indicated that anti-p20c would be useful in complementing anti-C100-3 for the diagnosis of NANB hepatitis and further decreasing the incidence of posttransfusion NANB hepatitis."
04/08/1992 - "Anti-p20c developed in the circulation of a patient with acute NANB hepatitis much earlier than anti-C100-3. "

11/01/1992 - "This anti-C25 assay detects all previously identified HCV-seropositive cases and provides a substantially more sensitive diagnostic for both acute and chronic HCV infections than the current anti-C100-3 (NS4) assay. "
07/01/1992 - "Out of 150 staff members, 3 (2%) were positive for anti-C100-3, whereas 25 (17%) were positive for anti-HBc (indicating prior HBV infection).(ABSTRACT TRUNCATED AT 250 WORDS)"
07/01/1992 - "Of 607 HD patients, 104 (17%) were positive for anti-C100-3 and 221 (36%) for HBV markers, indicating a much higher prevalence of HCV and HBV infection among HD patients than among ordinary blood donors (0.9% and 18%, respectively). "
07/01/1992 - "Of 159 patients without a history of blood transfusion, 17 (11%) were positive for anti-C100-3, showing that HCV infection can be acquired without transfusion. "
10/01/1994 - "To detect HCV infection accurately, the second-generation anti-HCV assays such as EIA, PHA and TND-2 were more useful than other assays such as anti-C100-3 antibody, anti-GOR antibody, and anti-JCC-2 antibody, because the second generation anti-HCV assays showed positive rates in over 90% of the cases with positive HCV-RNA. "

02/01/1993 - "To study anti-C100-3 hepatitis C antibody, 2023 plasma samples (10%) from group 1, 321 (30%) from group 2, and 327 (50%) from group 3 were randomly selected and tested. "
09/01/1994 - "These results indicate that the T3Ag-specific type 1 T helper cells play an important role in regulating anti-C100-3 antibody secretion in hepatitis C patients."
05/01/1993 - "Eight of 2,020 (0.4%) healthy blood donors who were negative for anti-C100-3 were anti-core-positive, and all 5 patients transfused with this anti-core positive blood suffered from posttransfusion hepatitis C. "
04/30/1993 - "In addition, hepatitis C virus RNA was detected in the earliest serum samples, 9 +/- 11 weeks before anti-C100-3, and thus may be valuable as a diagnostic marker for acute hepatitis C."

02/01/1993 - "Anti-C100-3 was detected frequently in each category of chronic non-A, non-B liver disease. "
02/01/1992 - "In the cryptogenic chronic liver disease cases 36% were positive for anti-C100-3 and 67% were positive for anti-c22 (p less than 0.001). "
02/01/1992 - "In the parenterally transmitted chronic liver disease group, 82% were positive for anti-C100-3 and 90% were positive for anti-c22 (not significant). "
02/01/1992 - "These results showed that HCV continues to replicate even in advanced liver disease and that it seems to be related to half of the cases of chronic non-A, non-B liver disease negative for anti-C100-3."
01/06/1990 - "Of fifteen chronic NANBH patients and one patient with chronic cryptogenic liver disease, ten were positive for anti-C100-3 and seven of the ten had viral sequences in their livers. "

05/01/1993 - "Anti-core was detected in 109/128 (85.2%) of patients with chronic hepatitis and the detection rate of anti-C100-3 was 95/128 (74.2%), respectively. "
05/01/1993 - "The authors measured antibody against the core protein of hepatitis C virus (HCV) in patients with acute or chronic hepatitis and healthy blood donors, and compared the results with the one obtained from anti-C100-3 assay. "
12/01/1993 - "Hepatitis C virus infection was found in 65 of 163 patients, as assessed by anti-c100-3 (ELISA 1), anti-c22-3, c33C (ELISA 2), and RIBA 2. Several histopathologic patterns were found in 33 liver samples from HCV-positive individuals: cirrhosis (n = 3), chronic active hepatitis (n = 14), chronic persistent hepatitis (n = 2), isolated hemosiderosis (n = 5), reactive hepatitis (n = 6), and others (n = 3). "